Compounds > vonoprazan
Page last updated: 2024-08-03 02:07:06

vonoprazan

Description

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine: a proton pump inhibitor; structure in first source [MeSH]

vonoprazan : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID15981397
CHEMBL ID2079130
SCHEMBL ID194487
CHEBI ID136048
MeSH IDM000609957

Synonyms (54)

Synonym
CHEBI:136048
vonoprazan
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
who 9535
1r5l3j156g ,
1-(5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
vonoprazan [usan:inn]
unii-1r5l3j156g
1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-
vonoprazan [usan]
vonoprazan [inn]
881681-00-1
SCHEMBL194487
vonoprazan [mi]
vonoprazan [who-dd]
CHEMBL2079130
CS-5555
HY-100007
tak-438 (free base)
DTXSID20236869 ,
1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine
HKT ,
1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonyl-pyrrol-3-yl]-~{n}-methyl-methanamine
(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine
881681-00-1 (free base)
NCGC00386236-05
AKOS030632802
tak-438 free base
DB11739
vonoprazan; tak-438 free base
5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine
Q27887191
vonoprazan free base
DS-19419
bdbm394392
us10308605, example 166
EX-A4002
tak-438;tak 438;tak438
BCP13240
SB16719
vonoprazan (usan/inn)
D11784
NCGC00386236-02
voquezna®
compound 13e [pmid: 22512618]
gtpl11549
EN300-7360476
{[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1h-pyrrol-3-yl]methyl}(methyl)amine
GLXC-25655
AC-36443
vonoprazanum
dtxcid00159360
a02bc08

Drug Classes (1)

ClassDescription
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.0684AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency18.9991AID1645840
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.8107AID1479145

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1910980Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta subunit in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
ISSN: 1520-4804		Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1891804Half life in Sprague-Dawley rat at 0.75 mg/kg, iv measured up to 24 hrs2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1891802Inhibition of gastric acid secretion in histamine induced Sprague-Dawley rat at 1 mg/kg, iv pretreated with compound for 15 mins followed by histamine dihydrochloride injection and measured after 3 hrs2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1891808Oral bioavailability in Sprague-Dawley rat at 2 mg/kg2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1891805AUC (0 to infinity) in Sprague-Dawley rat at 2 mg/kg, po2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1891807Cmax in Sprague-Dawley rat at 2 mg/kg, po2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1466557Dissociation constant, pKa of the compound2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
ISSN: 1464-3391		Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action.
AID1891806Half life in Sprague-Dawley rat at 2 mg/kg, po2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1891801Inhibition of rabbit stomach K+ stimulated H(+)/K(+) ATPase activity incubated for 30 mins in presence of ATP and KCl by malachite green reagent based assay2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391
AID1466558Lipophilicity, log D of the compound at pH 7.4 by HPLC analysis2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
ISSN: 1464-3391		Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action.
AID1891803AUC (0 to infinity) in Sprague-Dawley rat at 0.75 mg/kg, iv measured up to 24 hrs2022Bioorganic & medicinal chemistry, 06-15, Volume: 64ISSN: 1464-3391

Research

Studies (297)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's137 (46.13)24.3611
2020's160 (53.87)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials78 (26.09%)5.53%
Reviews53 (17.73%)6.00%
Case Studies15 (5.02%)4.05%
Observational8 (2.68%)0.25%
Other145 (48.49%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
porphobilinogen
0
aralkylamino compound;
dicarboxylic acid;
pyrroles		Escherichia coli metabolite;
metabolite;
mouse metabolite		00low000000
fpl 64176
0
carboxylic ester;
pyrroles		calcium channel agonist00low000000
SU5402
0
monocarboxylic acid;
oxindoles;
pyrroles		fibroblast growth factor receptor antagonist00low000000
tolmetin
0
aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug		00low000000
zomepirac
0
aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug		00low000000
n-methylpyrrole
0
pyrroles00low000000
2,5-dimethylpyrrole
0
pyrroles00low000000
pyrrole-2-carboxaldehyde
0
1,3-thiazole-2-carbaldehyde;
pyrroles		00low000000
pyrrolnitrin
0
alkaloid;
C-nitro compound;
monochlorobenzenes;
pyrroles		antifungal drug;
bacterial metabolite		00low000000
2-acetylpyrrole
0
aromatic ketone;
methyl ketone;
pyrroles		00low000000
pyoluteorin
0
aromatic ketone;
beta-hydroxy ketone;
diol;
organochlorine compound;
organochlorine pesticide;
polyketide;
pyrroles;
resorcinols		antibacterial agent;
antifungal agent;
apoptosis inducer;
bacterial metabolite;
marine metabolite		00low000000
clopirac
0
pyrroles00low000000
fendosal
0
benzoindole;
monohydroxybenzoic acid;
pyrroles		non-narcotic analgesic;
non-steroidal anti-inflammatory drug		00low000000
atorvastatin
0
aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic		00low000000
ro 5-3335
0
1,4-benzodiazepinone;
organochlorine compound;
pyrroles		anti-HIV-1 agent;
antineoplastic agent;
HIV-1 Tat inhibitor;
RUNX1 inhibitor		00low000000
fludioxonil
0
benzodioxoles;
nitrile;
organofluorine compound;
pyrroles		androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist		00low000000
fenpiclonil
0
dichlorobenzene;
nitrile;
pyrroles		antifungal agrochemical00low000000
chlorfenapyr
0
hemiaminal ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles		proacaricide;
proinsecticide		00low000000
pyrrolomycin a
0
antibiotic antifungal agent;
C-nitro compound;
organochlorine compound;
pyrroles		antibacterial agent;
bacterial metabolite		00low000000
Ethyl 2,5-dimethyl-1H-pyrrole-3-carboxylate
0
pyrroles00low000000
sceptrin
0
pyrroles;
secondary carboxamide		00low000000
4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile
0
monochlorobenzenes;
nitrile;
organobromine compound;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles		acaricide;
antifouling biocide;
insecticide		00low000000
orantinib
0
monocarboxylic acid;
oxindoles;
pyrroles		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist		00low000000
4-(2-methyl-5-phenyl-1-pyrrolyl)benzoic acid
0
pyrroles00low000000
pentabromopseudilin
0
pyrrolesmetabolite00low000000
2,6-bis(2-hydroxyphenyl)pyrrolo[3,4-f]isoindole-1,3,5,7-tetrone
0
pyrroles00low000000
3-(2,5-dimethyl-1-pyrrolyl)-4-methylaniline
0
pyrroles00low000000
2-[[3-acetyl-1-[4-(dimethylamino)phenyl]-2-methyl-5-indolyl]oxy]acetamide
0
pyrroles00low000000
3-[1-(2-furanylmethyl)-5-phenyl-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
LSM-23602
0
pyrroles00low000000
1-[1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanone
0
pyrroles00low000000
2-methyl-5-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)aniline
0
pyrroles00low000000
3-[1-(carboxymethyl)-5-phenyl-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
2-(4-fluorophenyl)-8-methylindolizine
0
pyrroles00low000000
2-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)aniline
0
pyrroles00low000000
3-(3-formyl-2,5-dimethyl-1-pyrrolyl)-4-methylbenzoic acid methyl ester
0
pyrroles00low000000
3-[5-(4-fluorophenyl)-1-(2-furanylmethyl)-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
3-[5-(4-methoxyphenyl)-1-prop-2-enyl-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid methyl ester
0
pyrroles00low000000
1-[2,5-dimethyl-1-(4-methylphenyl)-3-pyrrolyl]-2-([1,2,4]triazolo[4,3-a]pyridin-3-ylthio)ethanone
0
pyrroles00low000000
7-(diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol
0
pyrroles00low000000
5-(2-amino-4-thiazolyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methyl ester
0
pyrroles00low000000
2-(4-fluorophenyl)-1-indolizinecarboxylic acid ethyl ester
0
pyrroles00low000000
4-[7-(4-methylphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]morpholine
0
pyrroles00low000000
4-[7-(3-methylphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]morpholine
0
pyrroles00low000000
2-amino-N-(3-ethoxypropyl)-1-(4-sulfamoylphenyl)-3-pyrrolo[3,2-b]quinoxalinecarboxamide
0
pyrroles00low000000
6-(4-hydroxyphenyl)-5-(4-methoxyphenyl)-1,3-dimethylpyrrolo[3,4-d]pyrimidine-2,4-dione
0
pyrroles00low000000
1-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)thio]ethanone
0
pyrroles00low000000
N-[4-[[2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]phenyl]acetamide
0
pyrroles00low000000
3-[1-(3-methoxypropyl)-5-thiophen-2-yl-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
0
pyrroles00low000000
1-[1-(2-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-(4-methyl-1-piperidinyl)ethanone
0
pyrroles00low000000
3-[5-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1-benzopyran-2-one
0
pyrroles00low000000
2-Chloro-1-[2,5-dimethyl-1-(3-nitrophenyl)-1H-pyrrol-3-yl]ethan-1-one
0
pyrrolesanticoronaviral agent00low000000
4-hydroxybenzoic acid [2-[1-(2-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester
0
pyrroles00low000000
1-[1-(3-fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(1-methyl-5-tetrazolyl)thio]ethanone
0
pyrroles00low000000
2,4-diaziran-1-yl-6-(1-phenyl-1H-pyrrol-2-yl)-1,3,5-triazine
0
pyrroles00low000000
3-[5-(4-methylphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
3-[5-(4-methoxyphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
3-[5-(4-fluorophenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acid
0
pyrroles00low000000
1-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-[[4-methyl-5-(2-methyl-3-furanyl)-1,2,4-triazol-3-yl]thio]ethanone
0
pyrroles00low000000
2-[2-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-2-oxoethyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione
0
pyrroles00low000000
6-(3,4-dimethoxyphenyl)-4-oxo-3-phenyl-1,5,6,7-tetrahydroindole-2-carboxylic acid ethyl ester
0
pyrroles00low000000
N-[2-(tert-butylamino)-2-oxo-1-thiophen-2-ylethyl]-N-(2-oxolanylmethyl)-5-phenyl-1H-pyrrole-2-carboxamide
0
pyrroles00low000000
N-[2-(tert-butylamino)-2-oxo-1-pyridin-4-ylethyl]-N-(2-furanylmethyl)-5-phenyl-1H-pyrrole-2-carboxamide
0
pyrroles00low000000
2-(3-ethoxycarbonyl-2-methyl-5-phenyl-1-pyrrolyl)acetic acid
0
pyrroles00low000000
2-(3-acetyl-2-methyl-5-phenyl-1-pyrrolyl)-N-(thiophen-2-ylmethyl)acetamide
0
pyrroles00low000000
4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester
0
ethyl ester;
pyrroles;
tertiary carboxamide		00low000000
1-[3-[2-(dimethylamino)ethylamino]-3-oxopropyl]-2-methyl-5-(4-methylphenyl)-3-pyrrolecarboxylic acid ethyl ester
0
pyrroles00low000000
3-(1-methyl-2-benzimidazolyl)-1-phenyl-2-pyrrolo[3,2-b]quinoxalinamine
0
pyrroles00low000000
2-[[7-(4-methoxyphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]thio]propanoic acid ethyl ester
0
pyrroles00low000000
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine
0
pyrroles00low000000
N-cyclohexyl-1-(4-fluorophenyl)-2,5-dimethyl-3-pyrrolecarboxamide
0
pyrroles00low000000
6-oxo-4,5-dihydro-1H-pyridazine-3-carboxylic acid [1-[1-[4-(difluoromethoxy)phenyl]-2,5-dimethyl-3-pyrrolyl]-1-oxopropan-2-yl] ester
0
pyrroles00low000000
N-(cyclopentylideneamino)-4-(2,5-dimethyl-1-pyrrolyl)benzamide
0
pyrroles00low000000
5-[(3-methylphenoxy)methyl]-3-[4-(1-pyrrolyl)phenyl]-1,2,4-oxadiazole
0
pyrroles00low000000
1-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(6-methyl-2-nitro-3-pyridinyl)oxy]ethanone
0
pyrroles00low000000
3'-[2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]spiro[6,7-dihydro-5H-1-benzothiophene-4,5'-imidazolidine]-2',4'-dione
0
pyrroles00low000000
3-(1-methyl-2-benzimidazolyl)-1-(3-methylphenyl)-2-pyrrolo[3,2-b]quinoxalinamine
0
pyrroles00low000000
semaxinib
0
olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist		00low000000
su 11248
0
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		00low000000
oroidin
0
pyrroles;
secondary carboxamide		metabolite00low000000
su 5614
0
organochlorine compound;
oxindoles;
pyrroles		vascular endothelial growth factor receptor antagonist00low000000
tws 119
0
pyrroles00low000000
ageladine a
0
alkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite		00low000000
4-(2-phenylethylsulfamoyl)-1H-pyrrole-2-carboxylic acid methyl ester
0
pyrroles00low000000
marinopyrrole a
0
aromatic ketone;
organochlorine compound;
phenols;
pyrroles		antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite		00low000000
coumermycin
0
aromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles		antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor		00low000000
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone
0
pyrroles00low000000
saroglitazar
0
aromatic ether;
methyl sulfide;
monocarboxylic acid;
pyrroles		hypoglycemic agent;
PPARalpha agonist;
PPARgamma agonist		00low000000
5-[1-(4-chlorophenyl)-2,5-dimethyl-3-pyrrolyl]-N-methyl-6H-1,3,4-thiadiazin-2-amine
0
pyrroles00low000000
marineosin a
0
azaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles		antineoplastic agent;
metabolite		00low000000
marineosin b
0
azaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles		antineoplastic agent;
metabolite		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
lansoprazole
1
benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor		201720177.0low000010
sch 28080
1
imidazopyridine202220222.0low000001
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
1
isoquinolines202220222.0high000001
soraprazan
1
202220222.0medium000001
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
1-butanol
1
alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent		201920195.0low000010
histamine
3
aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter		201020239.3low000111
1-octanol
1
octanol;
primary alcohol		antifungal agent;
bacterial metabolite;
fuel additive;
kairomone;
plant metabolite		201920195.0low000010
urea
2
isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201620177.5low000020
aspirin
6
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		201720234.0low300033
berberine
1
alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker		202320231.0low100001
cimetidine
2
aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		201120208.5low000020
furazolidone
3
nitrofuran antibiotic;
oxazolidines		antibacterial drug;
antiinfective agent;
antitrichomonal drug;
EC 1.4.3.4 (monoamine oxidase) inhibitor		201720233.0low100012
indomethacin
2
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		201920223.5low000011
lansoprazole
36
benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor		201020235.2low210012312
metronidazole
18
C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic		201620235.5low3000144
midazolam
1
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		202320231.0low000001
omeprazole
6
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		202020232.8low100024
pirenzepine
1
pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist		202120213.0low100001
rabeprazole
17
benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor		201520234.6low7000116
opc 12759
1
secondary carboxamide201920195.0low100010
alanine
1
alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite		201920195.0low100010
carbostyril
1
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite201920195.0low100010
pyrroles
249
pyrrole;
secondary amine		201020234.9high6200116088
cycloguanil
2
triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		201920233.0low200011
potassium citrate
1
potassium saltdiuretic202320231.0low000001
dithiothreitol
1
1,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent		2010201014.0low000100
fluorine
1
diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound201920195.0low000010
amoxicillin
86
penicillin allergen;
penicillin		antibacterial drug201620233.5medium240003749
simvastatin
1
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug		202220222.0low000001
clopidogrel
5
methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		201820225.0low100041
acridine orange
1
aminoacridines;
aromatic amine;
tertiary amino compound		fluorochrome;
histological dye		2011201113.0low000010
voriconazole
1
conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor202020204.0low000010
atovaquone
2
hydroxy-1,2-naphthoquinone201920233.0low200011
clarithromycin
84
macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic		201620233.7medium250003846
bosentan anhydrous
1
primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist		202120213.0low000001
sch 28080
2
imidazopyridine2010201810.0low000110
levofloxacin
1
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor		201720177.0low000010
yh 1885
1
201920195.0low000010
ilaprazole
2
benzimidazoles;
sulfoxide		202220222.0low000002
tacrolimus
1
macrolide lactambacterial metabolite;
immunosuppressive agent		202120213.0low000001
lafutidine
1
organic molecular entity201820186.0low100010
bismuth
16
metal atom;
pnictogen		201720232.1low10000313
fumarates
5
butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite		201220235.4low000032
proguanil
2
biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		201920233.0low200011
sitafloxacin
3
201620205.7low100030
s 1743
26
magnesium saltanti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor		201520234.2low140001511
z 338
1
202320231.0low000001
bismuth tripotassium dicitrate
1
202320231.0low000001
prasugrel hydrochloride
4
201820195.8low000040
r-138727
1
organofluorine compound201920195.0low000010
gastrins
9
201520225.0low600063
piperidines
1
201820186.0low100010
tetracycline
3
201720233.7low000012
pyrimidinones
1
201920195.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Abdominal Injuries0
2
202220222.0low000002
Abdominal Pain0
3
201720233.0low000012
Absence Seizure0
1
202220222.0low000001
Acute Edematous Pancreatitis0
1
201920195.0low000010
Acute Liver Injury, Drug-Induced0
1
202120213.0low000001
Acute Respiratory Distress Syndrome0
1
202220222.0low000001
Adenocarcinoma0
2
202120213.0low000002
Adenocarcinoma, Basal Cell0
2
202120213.0low000002
Adenoma0
3
201620225.3low200021
Adenoma, Basal Cell0
3
201620225.3low200021
Adenomatous Polyps0
2
202220231.5low000002
Adverse Drug Event0
2
201720224.5low000011
Alcohol Drinking0
1
201920195.0low000010
Allergic Reaction0
3
201720233.0low000012
Anasarca0
1
201920195.0low000010
Anemia0
1
202320231.0low000001
Antibiotic-Associated Colitis0
2
201920233.0low000011
Atherogenesis0
1
201920195.0low000010
Atherosclerosis0
1
201920195.0low000010
Atrophy0
2
201620196.5low000020
Autoimmune Thrombocytopenia0
1
201820186.0low000010
Behavior Disorders0
1
202120213.0low000001
Benign Neoplasms0
2
202320231.0low000002
Bleeding0
4
201720233.8low000022
Blood Loss, Postoperative0
3
201920204.7low100030
Blood Loss, Surgical0
2
201920214.0low100011
Body Weight0
1
202120213.0low000001
Body Weight, Fetal0
1
201820186.0low000010
Cancer of Stomach0
26
201620234.2low100001610
Candida Infection0
1
201920195.0low000010
Candidiasis0
1
201920195.0low000010
Cardiovascular Diseases0
1
202320231.0low000001
Celiac Disease0
1
201920195.0low000010
Celiac Sprue0
1
201920195.0low000010
Chemical and Drug Induced Liver Injury0
1
202120213.0low000001
Cholera Infantum0
5
201620196.4low000050
Chronic Disease0
1
201820186.0low000010
Chronic Esophagitis, Eosinophilic0
3
201820223.7low000012
Chronic Illness0
1
201820186.0low000010
Clostridioides difficile Infection0
3
202120231.7low000003
Clostridium Infections0
3
202120231.7low000003
Colicky Pain0
3
201720233.0low000012
Colitis0
1
201720177.0low000010
Colonic Inertia0
1
202320231.0low000001
Colorectal Cancer0
3
201920232.7low000012
Colorectal Neoplasms0
3
201920232.7low000012
Complication, Postoperative0
11
201620205.8low4000110
Congenital Zika Syndrome0
1
202020204.0low000010
Constipation0
1
202320231.0low000001
Constriction, Pathologic0
1
202020204.0low000010
Constriction, Pathological0
1
202020204.0low000010
Curling Ulcer0
6
201520226.0low200051
Diarrhea0
2
202020232.5low100011
Disbacteriosis0
1
201920195.0low000010
Disease Exacerbation0
1
202320231.0low000001
Disease Models, Animal0
2
201920204.5low000020
Drug-Induced Stevens Johnson Syndrome0
1
202020204.0low000010
Drug-Related Side Effects and Adverse Reactions0
2
201720224.5low000011
Duodenal Ulcer0
6
201520226.0low200051
Dyspepsia0
1
202320231.0low000001
Edema0
1
201920195.0low000010
Enterocolitis, Pseudomembranous0
2
201920233.0low000011
Enteropathy, Exudative0
1
201920195.0low000010
Eosinophilic Esophagitis0
3
201820223.7low000012
Erythema Multiforme0
2
201620206.0low000020
Esophageal Hernia0
2
202020232.5low000011
Esophageal Reflux0
41
201120234.6low110002714
Esophagitis0
12
201520233.1low600039
Esophagitis, Peptic0
23
201620234.4low5000158
Esophagitis, Reflux0
23
201620234.4low5000158
Fetal Growth Restriction0
1
201820186.0low000010
Fetal Growth Retardation0
1
201820186.0low000010
Food Poisoning0
1
201920195.0low000010
Gastric Diseases0
2
201520197.0low000020
Gastric Ulcer0
25
201620234.9low11000196
Gastritis0
3
201920214.3low100021
Gastritis, Atrophic0
2
201620187.0low000020
Gastroduodenal Ulcer0
17
201220233.8low5000710
Gastroesophageal Reflux1
41
201120234.6low110002714
Gastrointestinal Hemorrhage0
9
201620235.1low400072
Heart Disease, Ischemic0
1
202020204.0low000010
Heartburn0
9
201620233.6low500045
Helicobacter Infections1
125
201520233.8medium290005966
Hematemesis0
1
201920195.0low100010
Hematochezia0
9
201620235.1low400072
Hemorrhage0
4
201720233.8low000022
Hyperkyphosis0
1
202020204.0low000010
Hyperplasia0
1
202320231.0low100001
Hypersensitivity0
3
201720233.0low000012
Hypoproteinemia0
1
201920195.0low000010
Indigestion0
1
202320231.0low000001
Infections, Helicobacter0
125
201520233.8medium290005966
Inflammation0
1
202020204.0low000010
Innate Inflammatory Response0
1
202020204.0low000010
Interstitial Nephritis0
1
202220222.0low000001
Intestinal Diseases0
1
202220222.0low000001
Intraductal Papillary Mucinous Neoplasms of the Pancreas0
1
201920195.0low000010
Intussusception0
1
202220222.0low000001
Laryngopharyngeal Reflux0
3
202220222.0low000003
Local Neoplasm Recurrence0
2
202220222.0low100002
Long Sleeper Syndrome0
1
201720177.0low100010
Melena0
1
201920195.0low100010
Mental Disorders0
1
202120213.0low000001
Myocardial Ischemia0
1
202020204.0low000010
Neoplasms0
2
202320231.0low000002
Nephritis, Interstitial0
1
202220222.0low000001
Nervous System Diseases0
1
201520159.0low100010
Nervous System Disorders0
1
201520159.0low100010
Orphan Diseases0
1
201720177.0low000010
Pancreatitis0
1
201920195.0low000010
Peptic Ulcer1
17
201220233.8low5000710
Polyps0
2
202220231.5low000002
Postoperative Complications0
11
201620205.8low4000110
Pregnancy0
1
201820186.0low000010
Protein-Losing Enteropathies0
1
201920195.0low000010
Purpura, Thrombocytopenic, Idiopathic0
1
201820186.0low000010
Pyrosis0
9
201620233.6low500045
Recrudescence0
9
201620205.8low600090
Regurgitation, Gastric0
3
202220222.0low000003
Respiratory Distress Syndrome0
1
202220222.0low000001
Scleroderma, Systemic0
1
202120213.0low000001
Sclerosis, Systemic0
1
202120213.0low000001
Seizures0
1
202220222.0low000001
Sensitivity and Specificity0
2
201620187.0low000020
Sleep Wake Disorders0
1
201720177.0low100010
Stevens-Johnson Syndrome0
1
202020204.0low000010
Stomach Neoplasms0
26
201620234.2low100001610
Stomach Ulcer0
25
201620234.9low11000196
Ulcer0
6
201920233.2low200033
Zika Virus Infection0
1
202020204.0low000010

Safety/Toxicity (29)

ArticleYear
Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Alimentary pharmacology & therapeutics, , Volume: 58, Issue:10		2023
Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
Helicobacter, , Volume: 28, Issue:5		2023
The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
European journal of medical research, , Aug-07, Volume: 28, Issue:1		2023
Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
Clinical and translational science, , Volume: 16, Issue:10		2023
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chinese medical journal, , Jul-20, Volume: 136, Issue:14		2023
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Clinical pharmacology in drug development, , Volume: 12, Issue:10		2023
Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
BMC gastroenterology, , May-01, Volume: 23, Issue:1		2023
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Digestion, , Volume: 104, Issue:4		2023
Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
Journal of gastroenterology, , Volume: 58, Issue:3		2023
Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
European journal of clinical pharmacology, , Volume: 79, Issue:2		2023
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Medicine, , Nov-25, Volume: 101, Issue:47		2022
Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis.
Revista espanola de enfermedades digestivas, , Volume: 115, Issue:6		2023
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a heali
Neurogastroenterology and motility, , Volume: 35, Issue:1		2023
Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in Ch
Helicobacter, , Volume: 27, Issue:5		2022
Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
Journal of clinical pharmacy and therapeutics, , Volume: 47, Issue:7		2022
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders.
Expert review of gastroenterology & hepatology, , Volume: 16, Issue:5		2022
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
British journal of clinical pharmacology, , Volume: 88, Issue:1		2022
Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study.
Die Pharmazie, , 10-01, Volume: 75, Issue:10		2020
Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
Helicobacter, , Volume: 25, Issue:5		2020
Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Digestive diseases and sciences, , Volume: 66, Issue:1		2021
Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Digestion, , Volume: 102, Issue:3		2021
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
Clinical and translational gastroenterology, , Volume: 10, Issue:11		2019
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Gut, , Volume: 69, Issue:2		2020
Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for
BioMed research international, , Volume: 2019		2019
Embryo-fetal toxicity assessment of vonoprazan in rats and rabbits.
Journal of applied toxicology : JAT, , Volume: 38, Issue:7		2018
Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Journal of gastroenterology, , Volume: 53, Issue:6		2018
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Alimentary pharmacology & therapeutics, , Volume: 45, Issue:2		2017
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Advances in therapy, , Volume: 33, Issue:9		2016
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Alimentary pharmacology & therapeutics, , Volume: 41, Issue:7		2015

Long-term Use (4)

ArticleYear
Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan.
Internal medicine (Tokyo, Japan), , Jan-01, Volume: 61, Issue:1		2022
Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Scandinavian journal of gastroenterology, , Volume: 53, Issue:8		2018
Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
Digestion, , Volume: 97, Issue:1		2018
A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Mar-15, Volume: 1015-1016		2016

Pharmacokinetics (14)

ArticleYear
Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
Clinical and translational science, , Volume: 16, Issue:10		2023
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Clinical pharmacology in drug development, , Volume: 12, Issue:10		2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
Alimentary pharmacology & therapeutics, , Volume: 58, Issue:1		2023
Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole.
Clinical pharmacokinetics, , Volume: 62, Issue:4		2023
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.
The American journal of gastroenterology, , 07-01, Volume: 117, Issue:7		2022
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure.
Journal of clinical pharmacology, , Volume: 62, Issue:6		2022
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
British journal of clinical pharmacology, , Volume: 88, Issue:1		2022
Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats.
Drug design, development and therapy, , Volume: 14		2020
Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Aug-01, Volume: 1059		2017
Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.
Clinical drug investigation, , Volume: 37, Issue:3		2017
Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men.
Clinical drug investigation, , Volume: 37, Issue:1		2017
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Advances in therapy, , Volume: 33, Issue:9		2016
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Clinical pharmacokinetics, , Volume: 55, Issue:4		2016
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Alimentary pharmacology & therapeutics, , Volume: 41, Issue:7		2015

Bioavailability (4)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019
A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
Journal of gastrointestinal and liver diseases : JGLD, , Volume: 25, Issue:3		2016
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Clinical pharmacokinetics, , Volume: 55, Issue:4		2016
Vonoprazan: first global approval.
Drugs, , Volume: 75, Issue:4		2015

Dosage (19)

ArticleYear
Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.
Trials, , Dec-01, Volume: 24, Issue:1		2023
Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Alimentary pharmacology & therapeutics, , Volume: 58, Issue:10		2023
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Helicobacter, , Volume: 28, Issue:6		2023
Vonoprazan-amoxicillin dual therapy for
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, , Volume: 29, Issue:6
Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
Helicobacter, , Volume: 28, Issue:5		2023
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Clinical pharmacology in drug development, , Volume: 12, Issue:10		2023
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, , Volume: 42, Issue:4		2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
Alimentary pharmacology & therapeutics, , Volume: 58, Issue:1		2023
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
The American journal of gastroenterology, , 04-01, Volume: 118, Issue:4		2023
Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan.
European journal of clinical pharmacology, , Volume: 78, Issue:6		2022
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
British journal of clinical pharmacology, , Volume: 88, Issue:7		2022
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure.
Journal of clinical pharmacology, , Volume: 62, Issue:6		2022
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.
Clinical pharmacology in drug development, , Volume: 11, Issue:2		2022
Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Helicobacter, , Volume: 23, Issue:2		2018
Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
European journal of clinical pharmacology, , Volume: 74, Issue:1		2018
Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Aug-01, Volume: 1059		2017
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Alimentary pharmacology & therapeutics, , Volume: 43, Issue:10		2016
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Clinical pharmacokinetics, , Volume: 55, Issue:4		2016
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Alimentary pharmacology & therapeutics, , Volume: 41, Issue:7		2015

Interactions (3)

ArticleYear
Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole.
Clinical pharmacokinetics, , Volume: 62, Issue:4		2023
Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
CPT: pharmacometrics & systems pharmacology, , Volume: 12, Issue:4		2023
Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men.
Clinical drug investigation, , Volume: 37, Issue:1		2017